Finding new treatments for muscular dystrophy with CRISPR-Cas9

Finding new treatments for muscular dystrophy with CRISPR-Cas9

Finding new treatments for muscular dystrophy with CRISPR-Cas9

A new study out of Boston's Children's Hospital has used the gene-editing tool CRISPR-Cas9 to explore the fatal genetic condition called facioscapulohumeral dystrophy (FSHD, one of the family of muscular dystrophies), and to test out the potential utility of various genes involved in this disorder. The research is published in the journal Science Translational Medicine.